48. Alterations in gene expression in cadaveric vs live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. Am J Transplant 2004, 4:1595-1604. (IF 8.9)

Kainz A, Mitterbauer C, Hauser P, Schwarz C, Regele HM, Berlakovich G, Mayer G, Perco P, Mayer B, Meyer TW and Oberbauer R.

47. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004, 43:1065-70. (IF 9.4)

Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Hörl WH, Haas M.

46. Sirolimus-based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a cotinuous combination of sirolimus and cyclosporine. J Am Soc Nephrol 2004, 15:809-17. (IF 10.3)

Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF, for the RMR Trial.

45. Genome wide gene expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest 2004, 84:353-361. (IF 5.1)

Hauser P, Schwarz C, Mitterbauer C, Regele MH, Mühlbacher F, Mayer G, Perco P, Mayer B, Meyer TW and Oberbauer R.

44. Non-Sustained Effect of Short-Term Bisphosphonate Therapy on Bone Turnover Three Years After Renal Transplantation. Kidney Int 2004, 65:304-309. (IF 14.8)

Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R.

SCIENTIFIC COLLABORATIONS